Monoclonal antibodies are big business. According to a report published by Deloitte, global sales of just the top 10 monoclonal antibodies amounted to $3.6 billion in 2009. That report asserted that "monoclonal antibodies (mAbs) have become one of the most valuable and rapidly growing segments of the worldwide pharmaceutical industry."But with their current extracellular reach, antibodies may literally have just scratched the surface of what is possible for them. Researchers, and a few intrepid companies, are working on ways to get antibodies into cells. Read More